Diagnostic imaging contrast agents with extended blood retention
View Patent ↗The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
1. A pharmaceutically acceptable salt of a diagnostic imaging contrast agent having a structure selected from the group consisting of:
wherein Ph=phenyl,
wherein Ph=phenyl,
wherein Ph=phenyl,
wherein Me=methyl,
wherein Ph=phenyl, and
wherein Ph=phenyl.
2. The pharmaceutically acceptable salt of claim 1 , wherein the salt is selected from the group consisting of calcium, sodium, N-methyl-glucamine, and mixtures thereof.
3. The pharmaceutically acceptable salt of claim 1 , wherein the diagnostic imaging contrast agent has the structure:
wherein Ph is phenyl, and wherein the salt is sodium.
4. The pharmaceutically acceptable salt of claim 1 , wherein the diagnostic imaging contrast agent has the structure:
wherein Ph is phenyl, and wherein the salt is N-methyl-glucamine.
5. The phannaceutically acceptable salt of claim 1 , wherein the diagnostic imaging contrast agent has the structure:
wherein Ph is phenyl, and wherein the salt is a mixture of sodium and N-methyl-glucamine.
6. A chelating ligand having the structure:
7. A chelating ligand having the structure:
8. A chelating ligand having the structure:
9. A chelating ligand having the structure:
10. A chelating ligand having the structure:
11. A chelating ligand having the structure:
12. A chelating ligand having the structure:
13. A chelating ligand having the structure:
14. A pharmaceutically acceptable salt of a chelating ligand according to any of claims 6 – 13 .
15. The pharmaceutically acceptable salt of claim 14 , wherein the salt is selected from the group consisting of calcium, sodium, N-methyl-glucamine, and mixtures thereof.